Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

In this paper, the group took aim at melanomas with a mutation in the NRAS gene (abbreviated as NRAS MUT melanoma). NRAS MUT melanoma accounts for about 30% of all melanoma cases, which has made ...

You have full access to this article via your institution. Serial dilutions were performed using DNA extracted from Nras mutation-bearing cell lines into placental DNA (wild-type). The assay ...

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

Beyond KRAS, patients with KRAS G12C-mutated colorectal cancers were most commonly characterized by alterations including both point mutations and amplifications of NRAS, BRAF, MAP2K1, and EGFR ...